| Literature DB >> 24160772 |
Jorien M Willems1, Tom Vlasveld, Wendy P J den Elzen, Rudi G J Westendorp, Ton J Rabelink, Anton J M de Craen, Gerard J Blauw.
Abstract
BACKGROUND: The question for prevalence estimation and validation of the various eGFRs in old age is still under debate. To assess renal function with increasing age, we estimated mean eGFR, in subjects aged 20-85 years. Furthermore, we assessed prevalence of eGFR in a population-based sample of 85 year olds and investigated the performance of these eGFRs in predicting mortality in the oldest old.Entities:
Mesh:
Year: 2013 PMID: 24160772 PMCID: PMC3827498 DOI: 10.1186/1471-2318-13-113
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Formulas of C-G, MDRD and CKD-EPI
| Cockroft-Gault | Female | All | ((140- age) × bodyweight/serum creatinine) × 0.85 |
| | Male | All | (140- age) × bodyweight/serum creatinine |
| MDRD | Female | All | 175 × (serum creatinine/88.4)- 1.154 × age-0.203 × 0.742 |
| | Male | All | 175 × (serum creatinine/88.4)- 1.154 × age-0.203 |
| CKD-EPI | Female | ≤ 62 | 144 × (serum creatinine/88.4/0.7)-0.329 × (0.993)age |
| | Female | > 62 | 144 × (serum creatinine/88.4/0.7)-1.209 x (0.993)age |
| | Male | ≤ 80 | 141 × (serum creatinine/88.4/0.7)-0.411 × (0.993)age |
| Male | > 80 | 141 × (serum creatinine/88.4/0.7)- 1.209 × (0.993)age |
*Serum creatinine is stated in μmol/L.
Abbreviations: eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease formula, CKD-EPI chronic kidney disease epidemiology equation.
Because all our individuals were of the Caucasian race the multiplier factor for race was not applied.
Stages of chronic kidney disease
| ≥ 60 | Stage 1 and 2 | Kidney damage with normal or mildly decreased GFR |
| 45–59 | Stage 3a | Moderately decreased GFR |
| 30–44 | Stage 3b | Moderately decreased GFR |
| < 30 | Stage 4 and 5 | Severely decreased GFR or kidney failure |
Adapted from K/DOQI clinical practice guidelines [13].
GFR is stated in ml/min/1.73 m2.
CKD stage 3 has been sub-divided into 30–44 (stage 3b) and 45–59 ml/min/1.73m2 (stage 3a) as there is evidence of graded increase in mortality risk [9,14].
Characteristics of the Bronovo study cohort (study 1)
| | ||||||
|---|---|---|---|---|---|---|
| | ||||||
| Female, n (%) | 23 (55) | 22 (51) | 23 (54) | 25 (50) | 23 (56) | 9 (43) |
| Creatinine (μmol/L) | 76 (71–87) | 85 (74–91) | 82 (72–97) | 86 (74–99) | 83 (74–93) | 87 (76–97) |
| Cockroft-Gault (ml/min) | 117 (97–127) | 112 (95–138) | 97 (82–112) | 87 (77–96) | 78 (68–85) | 57 (52–82) |
| MDRD (ml/min/1.73 m2) | 94 (85–102) | 86 (77–92) | 78 (72–87) | 75 (66–84) | 72 (66–82) | 69 (58–77) |
| CKD-EPI (ml/min/1.73 m2) | 104 (93–111) | 93 (83–99) | 82 (75–92) | 78 (68–87) | 71 (65–83) | 65 (54–73) |
Data presented are as median (IQR), unless otherwise stated.
Abbreviations: MDRD Modification of Diet in Renal Disease equation, CKD-EPI Chronic Kidney Disease Epidemiology Equation.
Figure 1Renal function in subjects of different age categories. Modification of Diet in Renal Disease (MDRD) clearance and Chronic Kidney Disease Epidemiology Collaboration clearance (CKD-EPI) are expressed in ml/min/1.73 m2 and Cockroft-Gault (C-G) clearance in ml/min.
Characteristics of subjects aged 85 of the Leiden 85-Plus study
| Female | 377 (67) |
| Comorbid illness | 398 (70) |
| Institutionalized | 104 (18) |
| MMSE | 26 (22–28) |
| Weight (kg) | 69.5 (61.5–78.3) |
| Length (cm) | 159 (154–166) |
| Body mass index (weigth/m2) | 26.7 (24.2–29.9) |
| Body surface area (m2)* | 1.72 (1.61–1.85) |
| Serum creatinine (μmol/L) | 92 (81–108) |
| Cockroft-Gault (ml/min)∫ | 43 (37–51) |
| >60 ml/min | 54 (10) |
| 30–60 ml/min | 454 (83) |
| <30 ml/min | 42 (7) |
| MDRD (ml/min/1.73 m2) | 58 (49–68) |
| >60 ml/min/1.73 m2 | 254 (45) |
| 30–60 ml/min/1.73 m2 | 298 (53) |
| <30 ml/min/1.73 m2 | 10 (2) |
| CKD-EPI (ml/min/1.73 m2) | 53 (46–62) |
| >60 ml/min/1.73 m2 | 179 (32) |
| 30–60 ml/min/1.73 m2 | 365 (65) |
| <30 ml/min/1.73 m2 | 18 (3) |
Continuous parameters are presented as median (IQR).
Categorial data are presented as number (%).
*Body Surface Area = calculated by DuBois’s formula.
∫ in 12 subjects weight was not available to calculate Cockroft-Gault clearance.
Abbreviations: MMSE Mini Mental State Examination, MDRD Modification of Diet in Renal Disease, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration clearance.
Figure 2Proportion of subjects in the various categories of eGFRs, calculated by C-G, MDRD and CKD-EPI. Abbreviations: C-G; Cockroft-Gault formula, MDRD; Modification of Diet in Renal Disease, CKD-EPI; Chronic Kidney Disease Epidemiology Collaboration clearance.
Number of subjects in categories of CKD assessed by MDRD and CKD-EPI
| CKD-EPI | <15 | 15-29 | 30-59 | 60-89 | >90 | |
| <15 | 0 | 0 | 0 | 0 | 2 | |
| 15-29 | 0 | 0 | 0 | 16 | ||
| 30-59 | 0 | 0 | 0 | 365 | ||
| 60-89 | 0 | 0 | 0 | 179 | ||
| >90 | 0 | 0 | 0 | 0 | 0 | |
| Total | 2 | 8 | 298 | 245 | 9 | 562 |
Numbers in bold indicate those subjects who do not change CKD category on the basis of eGFR assessed with MDRD and CKD-EPI. Italic figures indicate the numbers of subjects who change into a different CKD stage.
MDRD and CKD-EPI clearance are stated in ml/min/1.73 m2.
Abbreviations: CKD Chronic Kidney Disease, MDRD Modification of Diet in Renal Disease, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration clearance.
Relative mortality risks in categories of eGFR for C-G, MDRD and CKD-EPI
| | < 30 ml/min | 30-44 ml/min | 45-59 ml/min | >60 ml/min |
| C-G | 1.9 (1.1-3.3)* | 1.3 (0.9-1.9) | 1.0 (0.7-1.5) | 1 |
| MDRD | 3.5 (1.8-6.7)** | 1.6 (1.2-2.2)** | 1.1 (0.9-1.3) | 1 |
| CKD-EPI | 2.4 (0.9-6.4) | 1.3 (0.9-1.8) | 1.1 (0.9-1.5) | 1 |
All hazard ratios are adjusted for sex.
C-G clearance is in ml/min, MDRD and CKD-EPI clearance is in ml/min/1.73 m2.
Abbreviations: C-G Cockcroft-Gault, MDRD Modification of Diet in Renal Disease, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration clearance.
*P < 0.05, ** P ≤ 0.01 compared to the reference group (>60 ml/min).